Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Noah Gratch

Dermatology New York, NY Medical Doctor

NPI 1558380816 CMS profile 115699

820 2Nd Ave, 3A, New York, NY 10017

Open in the dashboard

General payments

$5,458

252 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Noah Gratch of New York, NY is reported in the CMS Open Payments database as having received $5,458 across 252 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,070 51
2024 General $1,149 58
2023 General $801 29
2022 General $790 46
2021 General $603 21
2020 General $277 14
2019 General $768 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Noah Gratch
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Noah Gratch were reported at $1,070. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Noah Gratch Dermatology median Middle half National median
2019 $768 $454 $129–$1,240 $163
2020 $277 $235 $81–$756 $114
2021 $603 $377 $108–$1,108 $132
2022 $790 $514 $143–$1,391 $149
2023 $801 $607 $159–$1,674 $160
2024 $1,149 $751 $204–$1,903 $164
2025 $1,070 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $892 37 payments
  2. LEO Pharma Inc. $872 38 payments
  3. Novartis Pharmaceuticals Corporation $865 54 payments
  4. AbbVie, Inc. $693 39 payments
  5. Genzyme Corporation $645 25 payments
  6. Pfizer Inc. $280 15 payments
  7. Merz North America, Inc. $183 2 payments
  8. Regeneron Healthcare Solutions, Inc. $159 7 payments
  9. Incyte Corporation $157 7 payments
  10. Sun Pharmaceutical Industries Inc. $150 7 payments
  11. Other $561 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,067 248 payments
  2. Education $391 4 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT $978 32 payments
  2. TREMFYA $797 31 payments
  3. ADBRY $627 26 payments
  4. COSENTYX Dermatology $466 26 payments
  5. SKYRIZI Immunology $268 14 payments
  6. COSENTYX Immunology $267 21 payments
  7. CIBINQO $233 12 payments
  8. SKYRIZI Immunology $220 11 payments
  9. STELARA $182 10 payments
  10. OPZELURA $157 7 payments
  11. Other $2,134 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

854

Median for Dermatology: 534

Drug cost

$261,733

Median for Dermatology: $67,151

Branded share of claims

8.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 16 $118,926
Dupixent Syringe Dupilumab Brand 16 $62,336
Dupixent Pen Dupilumab Brand 16 $55,868
Clobetasol Propionate Generic 146 $6,905
Fluocinonide Generic 80 $3,059
Pimecrolimus Generic 14 $3,032
Mycophenolate Mofetil Generic 12 $1,762
Triamcinolone Acetonide Generic 169 $1,754
Valacyclovir Valacyclovir Hcl Brand 27 $1,639
Tretinoin Generic 24 $1,623

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$430,193

Of which drugs: $27,066

Medicare patients

1,326

Average age 74

Services billed

8,126

654 women, 672 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 48%
Ischemic heart disease 32%
Diabetes 26%
Cancer 22%
Osteoporosis 17%
Chronic kidney disease 16%
Depression 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 68 87 $26,980
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 72 112 $85

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $153
  • SANOFI-AVENTIS U.S. LLC $92
  • Regeneron Healthcare Solutions, Inc. $48
$293 32 —
ADBRY
  • LEO Pharma Inc. $267
$267 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $196
$196 16 —
TREMFYA
  • Janssen Biotech, Inc. $157
$157 — —
SKYRIZI
  • AbbVie, Inc. $68
$68 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

252 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record